Hospital for Special Surgery, New York
This is a prospective, randomized controlled trial of patients undergoing minimally invasive transforaminal lumbar interbody fusion. This study will randomize patients into one of two groups: erector spinae plane (ESP) block and no ESP block.
Minimally invasive (MIS) spinal surgical procedures such as MIS transforaminal lumbar interbody fusion (TLIF) are being increasingly performed due to reduced morbidity. However, the mainstay for perioperative analgesia after these surgeries remains to be opioid pain medications, which have a number of associated adverse effects such as respiratory depression, hyperalgesia, and opioid habituation. Recently, the erector spinae plane (ESP) block has been introduced as an opioid-sparing regional anesthetic for lumbar spinal surgery with touted benefits including opioid use reduction and improved p…
Inclusion Criteria: * Age 18-80 * Patients scheduled for MIS TLIF (any level) with the principal investigator * ASA 1, 2, 3 Exclusion Criteria: * ASA 4 or higher * BMI \>40 * Chronic opioid use (daily use for \> 3 months) * Revision surgery, any history of previous lumbar spine surgery * Allergy to any of the study medications * Non-English speaking * Chronic renal insufficiency or failure (creatinine \>2) or severe hepatic disease (cirrhosis, failure) * Pregnancy * Any concomitant surgery
ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
Arctuva estimate
Verify or correct the compensation shown for this listing.